Carroll Financial Associates Inc. increased its position in Johnson & Johnson (NYSE:JNJ) by 2.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 90,732 shares of the company’s stock after buying an additional 2,529 shares during the period. Johnson & Johnson comprises approximately 1.8% of Carroll Financial Associates Inc.’s portfolio, making the stock its 10th largest position. Carroll Financial Associates Inc.’s holdings in Johnson & Johnson were worth $11,005,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Avalon Advisors LLC increased its position in shares of Johnson & Johnson by 32.7% in the first quarter. Avalon Advisors LLC now owns 410,880 shares of the company’s stock worth $44,457,000 after buying an additional 101,250 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Johnson & Johnson by 0.4% in the first quarter. Fisher Asset Management LLC now owns 10,854,263 shares of the company’s stock worth $1,195,923,000 after buying an additional 38,299 shares in the last quarter. British Columbia Investment Management Corp increased its position in shares of Johnson & Johnson by 1.0% in the second quarter. British Columbia Investment Management Corp now owns 1,649,232 shares of the company’s stock worth $200,052,000 after buying an additional 17,000 shares in the last quarter. Legal & General Group Plc increased its position in shares of Johnson & Johnson by 1.7% in the first quarter. Legal & General Group Plc now owns 13,449,262 shares of the company’s stock worth $1,455,269,000 after buying an additional 226,357 shares in the last quarter. Finally, Investec Asset Management LTD increased its position in shares of Johnson & Johnson by 49.2% in the first quarter. Investec Asset Management LTD now owns 5,050,411 shares of the company’s stock worth $546,454,000 after buying an additional 1,665,644 shares in the last quarter. 65.32% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.41% during mid-day trading on Friday, hitting $119.24. 4,799,292 shares of the stock were exchanged. The stock has a market capitalization of $326.23 billion, a P/E ratio of 22.22 and a beta of 0.62. Johnson & Johnson has a 12-month low of $94.12 and a 12-month high of $126.07. The stock’s 50 day moving average price is $118.85 and its 200-day moving average price is $117.07.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The firm earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. On average, equities research analysts expect that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

Several brokerages have recently commented on JNJ. RBC Capital Markets reiterated an “outperform” rating and set a $133.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Leerink Swann reiterated an “outperform” rating and set a $140.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $125.00 to $133.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 20th. BMO Capital Markets reiterated an “outperform” rating and set a $132.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Finally, Deutsche Bank AG reiterated a “hold” rating and set a $142.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research report on Thursday, July 21st. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $120.19.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares in the company, valued at approximately $19,728,953.19. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.